Trimetazidine | Rimecor tablets coated with film about 20 mg 30 pcs.
Special Price
$17.64
Regular Price
$25.00
In stock
SKU
BID464069
Latin name
Rimecor
Rimecor
Latin name
Rimecor
Release form
coated tablets 20 mg. On 10 or 30 tablets in a blister strip packaging. 60 tablets per polymer jar. Each jar or 1, 2, 3 or 6 blisters for 10 tablets, or 1 or 2 blisters for 30 tablets with instructions for use in a pack of cardboard.
Packing
30 pcs
Pharmacological action
Pharmacodynamics
Trimetazidine has an antianginal, antihypoxic effect. Directly affecting cardiomyocytes and brain neurons, it optimizes their metabolism and function. The cytoprotective effect is due to increased energy potential, activation of oxidative decarboxylation and rationalization of oxygen consumption (increased aerobic glycolysis and blockade of fatty acid oxidation). It supports myocardial contractility, prevents a decrease in the intracellular content of ATP and phosphocreatinin. Under conditions of acidosis, it normalizes the functioning of membrane ion channels, prevents the accumulation of calcium and sodium in cardiomyocytes, and normalizes the intracellular content of potassium ions. Reduces intracellular acidosis and phosphate levels due to myocardial ischemia and reperfusion. It prevents the damaging effect of free radicals, preserves the integrity of cell membranes, prevents the activation of neutrophils in the ischemic zone, increases the duration of the electric potential, reduces the yield of creatine phosphokinase from the cells and the severity of ischemic damage to the myocardium.
With angina pectoris it reduces the frequency of seizures (nitrate intake decreases), after 2 weeks of treatment, exercise tolerance increases, and blood pressure drops decrease. Hearing and results of vestibular tests in patients improve, dizziness and tinnitus are reduced.
With vascular pathology, the eye restores the functional activity of the retina.
Pharmacokinetics
After taking the drug inside, trimetazidine is rapidly and almost completely absorbed from the gastrointestinal tract. Bioavailability is 90%. The time to reach maximum plasma concentration is 2 hours (maximum concentration after a single dose of 20 mg of trimetazidine is about 55 ng / ml). It easily penetrates the histohematological barriers. The half-life (T1 / 2) is 4.5–5 hours. Communication with blood plasma proteins - 16%. It is excreted from the body by the kidneys (about 60% unchanged).
Indications
Coronary heart disease: prevention of angina attacks (in combination therapy)
Chorioretinal vascular disorders
Dizziness of vascular origin
Cochleo-vestibular disorders of ischemic nature (tinnitus, hearing impairment).
Use during pregnancy and lactation
The drug is contraindicated in pregnancy and lactation (breastfeeding).
Composition
1 coated tablet contains:
Active ingredient
Trimetazidine dihydrochloride 20 mg.
Excipients
ludipress, milk sugar (lactose), aerosil (silicon colloidal dioxide), croscarmellose sodium, magnesium stearate.
Shell
Hydroxy-propyl methylcellulose, titanium dioxide, talc, polyethylene glycol 4000, acid red.
Dosage and Administration
Inside, with meals.
Recommended dosage: 1 tablet (20 mg) 2-3 times a day (40-60 mg per day). The course of treatment is recommended by a doctor.
Side effects
The distribution of side effects by frequency was made according to the following gradation: very often - more than 1/10 often - more than 1/100 and less than 1/10 infrequently - more than 1/1000 and less than 1/100 rarely - more than 1 / 10000 and less than 1/1000 very rarely - less than 1/10000, including individual messages.
From the digestive system: often - abdominal pain, diarrhea, dyspepsia, nausea, vomiting.
From the side of the cardiovascular system: rarely - orthostatic hypotension, flushing of the face.
From the central nervous system: often - dizziness, headache very rarely - extrapyramidal disorders (tremor, stiffness, akinesia), reversible after discontinuation of the drug.
From the skin and subcutaneous tissue: often - rash, itching, urticaria.
Other: often - asthenia.
Storage Conditions
In a dry, dark place, out of reach of children, at a temperature not exceeding 25 РC.
Expiration
3 years
Terms leave through pharmacies
In retseptu
lekarstvennaja form
tablets
Indications
Coronary heart disease, Angina
Possible product names
RIMEKOR 0.02 N30 TABLE
RIMEKOR 0.02 N30 TABLE P / O
RIMEKOR REMOKR REM 0.02 20mg Tab. p / pl / rev X30
Rimekor 20mg No. 30
Nizhpharm, Russia
Rimecor
Release form
coated tablets 20 mg. On 10 or 30 tablets in a blister strip packaging. 60 tablets per polymer jar. Each jar or 1, 2, 3 or 6 blisters for 10 tablets, or 1 or 2 blisters for 30 tablets with instructions for use in a pack of cardboard.
Packing
30 pcs
Pharmacological action
Pharmacodynamics
Trimetazidine has an antianginal, antihypoxic effect. Directly affecting cardiomyocytes and brain neurons, it optimizes their metabolism and function. The cytoprotective effect is due to increased energy potential, activation of oxidative decarboxylation and rationalization of oxygen consumption (increased aerobic glycolysis and blockade of fatty acid oxidation). It supports myocardial contractility, prevents a decrease in the intracellular content of ATP and phosphocreatinin. Under conditions of acidosis, it normalizes the functioning of membrane ion channels, prevents the accumulation of calcium and sodium in cardiomyocytes, and normalizes the intracellular content of potassium ions. Reduces intracellular acidosis and phosphate levels due to myocardial ischemia and reperfusion. It prevents the damaging effect of free radicals, preserves the integrity of cell membranes, prevents the activation of neutrophils in the ischemic zone, increases the duration of the electric potential, reduces the yield of creatine phosphokinase from the cells and the severity of ischemic damage to the myocardium.
With angina pectoris it reduces the frequency of seizures (nitrate intake decreases), after 2 weeks of treatment, exercise tolerance increases, and blood pressure drops decrease. Hearing and results of vestibular tests in patients improve, dizziness and tinnitus are reduced.
With vascular pathology, the eye restores the functional activity of the retina.
Pharmacokinetics
After taking the drug inside, trimetazidine is rapidly and almost completely absorbed from the gastrointestinal tract. Bioavailability is 90%. The time to reach maximum plasma concentration is 2 hours (maximum concentration after a single dose of 20 mg of trimetazidine is about 55 ng / ml). It easily penetrates the histohematological barriers. The half-life (T1 / 2) is 4.5–5 hours. Communication with blood plasma proteins - 16%. It is excreted from the body by the kidneys (about 60% unchanged).
Indications
Coronary heart disease: prevention of angina attacks (in combination therapy)
Chorioretinal vascular disorders
Dizziness of vascular origin
Cochleo-vestibular disorders of ischemic nature (tinnitus, hearing impairment).
Use during pregnancy and lactation
The drug is contraindicated in pregnancy and lactation (breastfeeding).
Composition
1 coated tablet contains:
Active ingredient
Trimetazidine dihydrochloride 20 mg.
Excipients
ludipress, milk sugar (lactose), aerosil (silicon colloidal dioxide), croscarmellose sodium, magnesium stearate.
Shell
Hydroxy-propyl methylcellulose, titanium dioxide, talc, polyethylene glycol 4000, acid red.
Dosage and Administration
Inside, with meals.
Recommended dosage: 1 tablet (20 mg) 2-3 times a day (40-60 mg per day). The course of treatment is recommended by a doctor.
Side effects
The distribution of side effects by frequency was made according to the following gradation: very often - more than 1/10 often - more than 1/100 and less than 1/10 infrequently - more than 1/1000 and less than 1/100 rarely - more than 1 / 10000 and less than 1/1000 very rarely - less than 1/10000, including individual messages.
From the digestive system: often - abdominal pain, diarrhea, dyspepsia, nausea, vomiting.
From the side of the cardiovascular system: rarely - orthostatic hypotension, flushing of the face.
From the central nervous system: often - dizziness, headache very rarely - extrapyramidal disorders (tremor, stiffness, akinesia), reversible after discontinuation of the drug.
From the skin and subcutaneous tissue: often - rash, itching, urticaria.
Other: often - asthenia.
Storage Conditions
In a dry, dark place, out of reach of children, at a temperature not exceeding 25 РC.
Expiration
3 years
Terms leave through pharmacies
In retseptu
lekarstvennaja form
tablets
Indications
Coronary heart disease, Angina
Possible product names
RIMEKOR 0.02 N30 TABLE
RIMEKOR 0.02 N30 TABLE P / O
RIMEKOR REMOKR REM 0.02 20mg Tab. p / pl / rev X30
Rimekor 20mg No. 30
Nizhpharm, Russia
Write Your Own Review